Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000001808

Price
40.69 CNY
Market cap
31.34 bn CNY
P/E (2025)
7.64
P/S (2025)
6.37
Dividend yield
11.77 %
Net margin
43.34 %
Return on equity (ROE)
30.02 %
Return on assets (ROA)
18.23 %

Tianjin Zhongxin Pharmaceutical Group Corp Ltd financials

Fiscal year20242025
Revenue7.31 bn CNY4.92 bn CNY
Gross profit3.50 bn CNY3.64 bn CNY
Operating income2.57 bn CNY971.15 m CNY
EBIT774.04 m CNY2.50 bn CNY
Net income2.23 bn CNY2.13 bn CNY
Diluted EPS – continuing operations2.89 CNY5.33 CNY

Full history since 1998, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Tianjin Zhongxin Pharmaceutical Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.